Global Health Ltd

Net profit of Global Health declined 20.40% to Rs 101.40 crore in the quarter ended March 2025 as against Rs 127.38 crore during the previous quarter ended March 2024. Sales rose 15.16% to Rs 931.25 crore in the quarter ended March 2025 as against Rs 808.63 crore during the previous quarter ended March 2024. For the full year,net profit rose 0.68% to Rs 481.44 crore in the year ended March 2025 as against Rs 478.19 crore during the previous year ended March 2024. Sales rose 12.74% to Rs 3692.32 crore in the year ended March 2025 as against Rs 3275.11 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales931.25808.63 15 3692.323275.11 13 OPM %24.1322.18 -23.7524.40 - PBDT232.59188.54 23 890.91799.83 11 PBT183.34143.09 28 697.16627.10 11 NP101.40127.38 -20 481.44478.19 1 Powered by Capital Market - Live

Global Health announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 25%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Global Health has allotted 73,000 equity shares to GHL Employee Welfare Trust ('ESOP Trust') under Part -B of GHL LTIP 2024 Plan i.e. GHL Employees Stock Purchase Scheme, 2024. Post allotment, the paid up equity share capital has increased to Rs. 53,73,20,764/- divided into 26,86,60,382 equity shares of Rs. 2/- each.Powered by Capital Market - Live

Global Health will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live

Global Health 'Medanta' announced its entry into the North East with its plan to establish a super speciality hospital in Guwahati. The Board of Directors, in its meeting held today, approved the purchase of 3 acres of land from Assam Electricity Grid Corporation for Rs. 30 crore plus incidental expenses for registration and possession of the land. The Board has also approved plans to invest approximately Rs. 500 crore including cost of land in developing a state-of-the-art, 400-bed super specialty hospital. Proposed site is strategically located on National Highway 27, offering seamless connectivity across the entire North East region. This expansion aims to strengthen healthcare infrastructure and will serve over 50 million people across Assam and its neighbouring states. Medanta's foray into the region will be transformative, bringing world-class medical expertise, cutting-edge technology and comprehensive care across more than 20 super specialties, including transplants and advanced robotic procedures. Powered by Capital Market - Live

Global Health has approved the grant of 5,85,500 Options and Offer of 2,03,000 Shares to certain eligible employees under Part -A and Part- B of GHL Long Term Share Based Incentive Plan - 2024 (GHL LTIP 2024 Plan), respectively.Powered by Capital Market - Live

The company intends to develop a super speciality hospital on this land. Global Health operates hospitals in Gurugram, Indore, Ranchi, Lucknow and Patna. The company's consolidated operational bed count stood at nearly 2,373 beds as on 31 March 2024. The scrip fell 1.71% to currently trade at Rs 1212 on the BSE. Powered by Capital Market - Live

Crisil Ratings stated that GHL's Revenue reported 12% on-year growth in the first nine months of fiscal 2025, driven by increase in inpatient volumes owing to bed expansion, improvement in average revenue per occupied bed (ARPOB) and sustenance of occupancy levels on year on-year basis. Operating profitability moderated by 50 basis points (bps) to 24.1% in the first nine months of fiscal 2025 due to decline in operating profitability in the Lucknow hospital while the Patna (Bihar) and Gurugram (Haryana) hospitals registered stable profitability. At a consolidated level, GHL's revenue may grow 10-12% in fiscal 2025, supported by bed additions, sustenance of occupancy levels at overall level and improvement in ARPOB due to change in case mix. Operating profitability is expected to sustain at 22-24% despite the moderation expected in the Lucknow hospital due to better profitability in other hospitals, although pre-operative expenses towards bed additions at existing hospitals and commencement of the hospital at Noida (Uttar Pradesh) expected towards the end of fiscal 2025 might partly constrain profitability. On consolidated basis, revenue grew 21% to Rs 3,278 crore in fiscal 2024 (from Rs 2,712 crore in fiscal 2023), driven by higher inpatient volumes, changes in specialty mix towards higher value specialties leading to better ARPOB as well as better scale up of the Lucknow and Patna hospitals. The financial risk profile is supported by strong capital structure, healthy debt protection metrics and liquidity. Consolidated adjusted networth stood at Rs 2,900 crore and debt (including lease liabilities) at Rs 802 crore as on 31 March 2024, with gearing at 0.28 time. GHL has planned capital expenditure (capex) of more than Rs ~2,500 crore over the next 3-5 fiscals. The capex will be funded through a prudent mix of cash accrual and debt. Even though the company may avail of external debt, gearing is expected below 0.5 time over the medium term. The ratings continue to reflect the experienced management of GHL in therapeutic segments and healthy financial risk profile. These strengths are partially offset by risks related to implementation and timely stabilisation of upcoming hospitals, geographic and therapeutic segmental concentration in revenue and exposure to intense competition. Global Health operates hospitals in Gurugram, Indore, Ranchi, Lucknow and Patna. The company's consolidated operational bed count stood at nearly 2,373 beds as on 31 March 2024. The scrip shed 0.64% to currently trade at Rs 1227.95 on the BSE. Powered by Capital Market - Live

Global Health has received affirmation in credit ratings from CRISIL Ratings pursuant to merger of Medanta Holdings (MHPL), erstwhile wholly owned subsidiary with the Company as per below details: Total Bank Loan Facilities Rated - Rs. 1500 crore* (Enhanced from Rs. 950 crore) Long Term Rating - CRISIL AA-/Positive (Reaffirmed) Short-term rating - CRISIL A1+ (Reaffirmed) *Earlier rating of MHPL was for Rs. 550 crore which was added in approved limit of GHL i.e. Rs. 950 crore. Powered by Capital Market - Live

Global Health has received reaffirmation in credit rating for bank facilities of Rs 950 crore at CRISIL AA-; Positive/ CRISIL A1+. Powered by Capital Market - Live